Indirect treatment comparison of the efficacy of olaparib 300 mg tablets BID and cabazitaxel 25 mg/m2 every 3 weeks plus daily prednisolone and granulocyte colony-stimulating factor in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Tim Reason,Charles McCrea,Robert Hettle,S. Ghate,Christian Heinrich Poehlein,David Olmos

Indirect treatment comparison of the efficacy of olaparib 300 mg tablets BID and cabazitaxel 25 mg/m2 every 3 weeks plus daily prednisolone and granulocyte colony-stimulating factor in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

2021

Tim Reason
Charles McCrea
Robert Hettle
S. Ghate
Christian Heinrich Poehlein
David Olmos

5051Background: In PROfound, olaparib demonstrated improved radiological PFS (rPFS) and overall survival (OS) versus new hormonal agent (NHA) in patients with homologous recombination repair mutate...

Keywords:

Prednisolone
Medicine
Cabazitaxel
Hormone
Oncology
Granulocyte colony-stimulating factor
Internal medicine
Indirect Treatment
Prostate cancer
castration resistant
Olaparib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations